Synthaverse S.A. (WSE:SVE)

Market Cap	351.36M
Revenue (ttm)	62.66M
Net Income (ttm)	4.45M
Shares Out	70.27M
EPS (ttm)	0.06
PE Ratio	79.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,211
Average Volume	106,683
Open	5.02
Previous Close	5.00
Day's Range	4.95 - 5.06
52-Week Range	3.95 - 5.93
Beta	1.81
RSI	66.05
Earnings Date	Sep 5, 2025

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 239
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SVE

Financial Performance

In 2023, Synthaverse's revenue was 58.61 million, an increase of 16.32% compared to the previous year's 50.38 million. Earnings were 4.76 million, a decrease of -21.76%.